Novartis’ Phase II SAF312 has a nine-point increase in chances to transition to next development …,

The change occurred after a series of updates were made to the Phase II study’s ClinicalTrials.gov entry, between 6 May and 4 June. These included …, The change occurred after a series of updates were made to the Phase II study’s ClinicalTrials.gov entry, between 6 May and 4 June. These included …, Read More

Scroll to Top